DAO and schizophrenia: However, despite increasingly robust evidence for cerebellar involvement in schizophrenia and for the cerebellum as the main site of action of luvadaxistat and other DAAO inhibitors, the link between these molecular effects and the impact on behavior in rodent models or psychiatric symptoms in individuals with schizophrenia is, as yet, poorly understood and an avenue for future exploration.